Fig. 2From: Comparison of cardiovascular outcomes between SGLT2 inhibitors in diabetes mellitusRisk of Cardiovascular Event among SGLT2 Inhibitors. We compared the risks of HF, MI, AP, stroke, and AF between individual SGLT2 inhibitors. Incidence rates were presented as per 10,000 person-yearsBack to article page